DK2840090T3 - Antistofrensning ved kationbytningskromatografi - Google Patents
Antistofrensning ved kationbytningskromatografi Download PDFInfo
- Publication number
- DK2840090T3 DK2840090T3 DK14189095.4T DK14189095T DK2840090T3 DK 2840090 T3 DK2840090 T3 DK 2840090T3 DK 14189095 T DK14189095 T DK 14189095T DK 2840090 T3 DK2840090 T3 DK 2840090T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- ser
- thr
- val
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Claims (3)
1. Anvendelse af en ækvilibreringsbuffer omfattende 13-33 mM MES og 50 - 70 mM NaCI med en pH på 5,1-5,9, en første vaskebuffer omfattende 15-35 mM MOPs med en pH på 6,6 - 7,4, en anden vaskebuffer omfattende 13-33 mM MES og 5 - 20 mM NaCI med en pH på 5,1 - 5,9 og en elueringsbuffer omfattende 13-33 mM MES og 160 - 190 mM NaCI med en pH på 5,4-5,6 til oprensning af bevacizumab.
2. Anvendelse ifølge krav 1, yderligere omfattende anvendelse af en ækvilibreringsbuffer omfattende 23 mM MES og 60 mM NaCI med en pH på 5,5 og en ledeevne på 6,9 mS/cm, en første vaskebuffer omfattende 25 mM MOPS med en pH på 7,0, en anden vaskebuffer omfattende 23 mM MES og 10 mM NaCI med en pH på 5,5 og ledeevne på 1,5 mS/cm og en elueringsbuffer omfattende 23 mM MES og 175 mM NaCI med en pH på 5,5 og en ledeevne på 18 mS/cm til oprensning af bevacizumab.
3. Anvendelse ifølge krav 1, yderligere omfattende anvendelse af en ækvilibreringsbuffer omfattende 23 mM MES og 60 mM NaCI med en pH på 5,4 - 5,60 og en ledeevne på 6,1 - 7,7 mS/cm, en første vaskebuffer omfattende 25 mM MOPS med en pH på 6,9-7,1 og en ledeevne på 0,2 -1,2 mS/cm, en anden vaskebuffer omfattende 23 mM MES og 10 mM NaCI med en pH på 5,4 - 5,6 og en ledeevne på 1,2 - 1,8 mS/cm og en elueringsbuffer omfattende 23 mM MES og 175 mM NaCI med en pH på 5,45 - 5,55 og en ledeevne på 17,5 - 18,5 mS/cm til oprensning af bevacizumab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98382507P | 2007-10-30 | 2007-10-30 | |
EP08844379.1A EP2215117B2 (en) | 2007-10-30 | 2008-10-29 | Antibody purification by cation exchange chromatography |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2840090T3 true DK2840090T3 (da) | 2018-04-23 |
Family
ID=40262967
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12189190.7T DK2565206T3 (da) | 2007-10-30 | 2008-10-29 | Antistofrensning ved kationbytningskromatografi |
DK08844379.1T DK2215117T4 (da) | 2007-10-30 | 2008-10-29 | Antistofrensning ved kationbytningschromatografi |
DK14189095.4T DK2840090T3 (da) | 2007-10-30 | 2008-10-29 | Antistofrensning ved kationbytningskromatografi |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12189190.7T DK2565206T3 (da) | 2007-10-30 | 2008-10-29 | Antistofrensning ved kationbytningskromatografi |
DK08844379.1T DK2215117T4 (da) | 2007-10-30 | 2008-10-29 | Antistofrensning ved kationbytningschromatografi |
Country Status (32)
Country | Link |
---|---|
US (3) | US20090148435A1 (da) |
EP (4) | EP3441402A1 (da) |
JP (5) | JP5237382B2 (da) |
KR (3) | KR20150008503A (da) |
CN (3) | CN105315323A (da) |
AR (2) | AR069097A1 (da) |
AU (1) | AU2008318865B2 (da) |
BR (1) | BRPI0817182A2 (da) |
CA (1) | CA2703279C (da) |
CL (1) | CL2008003218A1 (da) |
CO (1) | CO6280422A2 (da) |
CY (1) | CY1116129T1 (da) |
DK (3) | DK2565206T3 (da) |
ES (3) | ES2666170T3 (da) |
HK (4) | HK1143821A1 (da) |
HR (2) | HRP20150282T4 (da) |
HU (3) | HUE027668T2 (da) |
IL (4) | IL205310A0 (da) |
ME (1) | ME02101B (da) |
MX (1) | MX2010004740A (da) |
NZ (1) | NZ584839A (da) |
PE (1) | PE20091434A1 (da) |
PH (1) | PH12013501128A1 (da) |
PL (3) | PL2565206T3 (da) |
PT (1) | PT2215117E (da) |
RS (1) | RS53850B2 (da) |
RU (1) | RU2498991C2 (da) |
SG (2) | SG175597A1 (da) |
SI (3) | SI2215117T2 (da) |
TW (2) | TWI448330B (da) |
WO (1) | WO2009058812A1 (da) |
ZA (2) | ZA201002850B (da) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA036531B1 (ru) * | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CN102580084B (zh) * | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
CN103251946A (zh) | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
MX346523B (es) | 2006-09-13 | 2017-03-23 | Abbvie Inc | Mejoras de cultivos celulares. |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
EP3441402A1 (en) | 2007-10-30 | 2019-02-13 | Genentech, Inc. | Antibody purification by cation exchange chromatography |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
CN105111309A (zh) | 2008-10-20 | 2015-12-02 | Abbvie公司 | 使用a蛋白亲和层析分离和纯化抗体 |
SG195577A1 (en) | 2008-10-20 | 2013-12-30 | Abbott Lab | Viral inactivation during purification of antibodies |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
US20120178910A1 (en) | 2009-09-23 | 2012-07-12 | Medarex, Inc. | Cation exchange chromatography (methods) |
TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
CA2795043C (en) | 2010-03-30 | 2019-04-23 | Janssen Biotech, Inc. | Humanized il-25 antibodies |
SI2772265T1 (en) | 2010-05-14 | 2018-06-29 | Oregon Health & Science University | HCMV AND RHCMV RECOMBINANT VECTORS AND THEIR APPLICATIONS |
MY161534A (en) * | 2010-05-25 | 2017-04-28 | Genentech Inc | Methods of purifying polypeptides |
GB201012603D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
RU2586515C2 (ru) | 2010-12-21 | 2016-06-10 | Ф.Хоффманн-Ля Рош Аг | Препарат антитела, обогащенного изоформами и способ его получения |
JP6147726B2 (ja) * | 2011-03-29 | 2017-06-14 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | タンパク質精製のためのバッファー系 |
EP2714713B1 (en) * | 2011-05-26 | 2018-05-09 | Dr. Reddy's Laboratories Limited | Purification of anti-cd20 antibodies |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
WO2013054250A1 (en) * | 2011-10-10 | 2013-04-18 | Dr Reddy's Laboratories Limited | Purification method |
MX2014004021A (es) | 2011-10-14 | 2014-04-30 | Genentech Inc | Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab. |
RU2478646C1 (ru) * | 2011-11-28 | 2013-04-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биологии им.В.А.Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения высокоаффинных поликлональных антител |
RU2648999C2 (ru) | 2011-12-22 | 2018-03-29 | Дженентек, Инк. | Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии |
WO2014009465A1 (en) | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
US20150218208A1 (en) * | 2012-08-27 | 2015-08-06 | Asahi Kasei Medical Co., Ltd. | Method for purifying antibody by temperature-responsive chromatography |
CN103217499B (zh) * | 2013-01-15 | 2015-12-02 | 珠海市丽珠单抗生物技术有限公司 | 一种测定免疫球蛋白电荷异构体的糖基化和末端修饰情况的方法 |
RU2662929C2 (ru) * | 2013-03-08 | 2018-07-31 | Джензим Корпорейшн | Интегрированное непрерывное производство терапевтических белковых лекарственных веществ |
UY35517A (es) * | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
EP2986643A2 (en) | 2013-04-16 | 2016-02-24 | F. Hoffmann-La Roche AG | Pertuzumab variants and evaluation thereof |
US10351592B2 (en) | 2013-10-30 | 2019-07-16 | Celltrion, Inc. | Method for separating antibody isoforms using cation exchange chromatography |
CN104628846B (zh) * | 2013-11-06 | 2019-12-06 | 三生国健药业(上海)股份有限公司 | 重组蛋白质的纯化方法 |
CA2928238C (en) * | 2013-11-25 | 2021-08-17 | Seattle Genetics, Inc. | Preparing antibodies from cho cell cultures for conjugation |
TWI709570B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析法及製法 |
TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
EP3102589A1 (en) * | 2014-02-04 | 2016-12-14 | Biogen MA Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
JP6293907B2 (ja) | 2014-03-10 | 2018-03-14 | リヒター ゲデオン エヌワイアールティー. | プレクリーニング工程を用いた免疫グロブリンの精製 |
CN105017418B (zh) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | 单克隆抗体纯化工艺方法 |
SG10201809411PA (en) | 2014-04-25 | 2018-11-29 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
KR102403547B1 (ko) | 2014-07-16 | 2022-05-30 | 오레곤 헬스 앤드 사이언스 유니버시티 | 외인성 항원을 포함하는 인간 시토메갈로바이러스 |
CN105315369B (zh) * | 2014-07-25 | 2020-03-13 | 山东博安生物技术有限公司 | 利用阳离子交换层析纯化蛋白质 |
WO2016149088A1 (en) * | 2015-03-13 | 2016-09-22 | Bristol-Myers Squibb Company | Use of alkaline washes during chromatography to remove impurities |
WO2016196373A2 (en) | 2015-05-30 | 2016-12-08 | Genentech, Inc. | Methods of treating her2-positive metastatic breast cancer |
KR101657690B1 (ko) * | 2015-06-05 | 2016-09-19 | 주식회사 녹십자홀딩스 | 혈장 유래 b형 간염 사람 면역글로불린 제제의 제조방법 |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
CA3005136A1 (en) | 2015-11-20 | 2017-05-26 | Oregon Health & Science University | Cmv vectors comprising microrna recognition elements |
GB201600512D0 (en) * | 2016-01-12 | 2016-02-24 | Univ York | Recombinant protein production |
KR102574810B1 (ko) | 2016-04-15 | 2023-09-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 습성 연령 관련 황반 변성의 치료를 위한 조성물 |
CN109310756B (zh) * | 2016-05-13 | 2022-06-28 | 奥美药业有限公司 | 新型血管生成素2,vegf双特异性拮抗剂 |
KR20220158870A (ko) * | 2016-07-15 | 2022-12-01 | 에프. 호프만-라 로슈 아게 | Peg화 에리트로포이에틴을 정제하기 위한 방법 |
CN106222222B (zh) * | 2016-08-08 | 2019-10-29 | 湖北医药学院 | 一种重组人白血病抑制因子的制备方法 |
WO2018045587A1 (zh) * | 2016-09-12 | 2018-03-15 | 广东东阳光药业有限公司 | 一种抗vegf类单克隆抗体的纯化方法 |
CN106380519B (zh) * | 2016-10-17 | 2019-11-01 | 深圳万乐药业有限公司 | 一种单克隆抗体的纯化方法 |
JP2019531745A (ja) | 2016-10-18 | 2019-11-07 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 主要組織適合遺伝子複合体e分子によって拘束されるt細胞を誘発するサイトメガロウイルスベクター |
EP3532498A1 (en) * | 2016-10-31 | 2019-09-04 | Hexal AG | Antibody preparation |
MX2019007801A (es) | 2016-12-28 | 2019-10-30 | Genentech Inc | Tratamiento de cáncer avanzado con expresión de her2. |
HUE052551T2 (hu) | 2017-01-17 | 2021-05-28 | Genentech Inc | Szubkután HER2 antitest készítmények |
AU2018227788B2 (en) | 2017-03-02 | 2021-04-22 | F. Hoffmann-La Roche Ag | Adjuvant treatment of HER2-positive breast cancer |
BE1025090B1 (fr) * | 2017-03-30 | 2018-10-29 | Univercells Sa | Procede et kit de purification de proteines |
AR111465A1 (es) * | 2017-04-14 | 2019-07-17 | Cj Healthcare Corp | Método para la purificación de anticuerpos análogos por el uso de cromatografía de intercambio de cationes |
CA3059241A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
US11426706B2 (en) | 2017-06-21 | 2022-08-30 | Cephalon, Inc. | Cation exchange chromatography wash buffer |
SG11202001401TA (en) * | 2017-09-22 | 2020-04-29 | Immunogen Inc | Separation of triple-light chain antibodies using cation exchange chromatography |
CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
WO2019191416A1 (en) * | 2018-03-29 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of purifying monomeric monoclonal antibodies |
WO2019217570A1 (en) * | 2018-05-08 | 2019-11-14 | Waters Technologies Corporation | Methods, compositions and kits useful for ph gradient cation exchange chromatography |
EP3843869A1 (en) | 2018-08-31 | 2021-07-07 | Genzyme Corporation | Sterile chromatography resin and use thereof in manufacturing processes |
EP3643322A1 (en) * | 2018-10-26 | 2020-04-29 | Mabion SA | Low aggregate anti cd20 ligand formulation |
CN109320611B (zh) * | 2018-10-31 | 2022-06-03 | 鼎康(武汉)生物医药有限公司 | 一种人鼠嵌合单克隆抗体生物类似药的纯化方法 |
CN112206327A (zh) * | 2019-07-12 | 2021-01-12 | 上海药明生物技术有限公司 | 一种抗体偶联药物的制备及其高通量筛选方法 |
CN114599971A (zh) * | 2019-10-14 | 2022-06-07 | 皮尔斯生物科技有限公司 | 肽纯化配制物和方法 |
CN112830972A (zh) * | 2019-11-25 | 2021-05-25 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途 |
KR102153258B1 (ko) * | 2020-02-21 | 2020-09-07 | 프레스티지바이오로직스 주식회사 | 베바시주맙 정제의 최적화된 방법 |
US11416468B2 (en) * | 2020-07-21 | 2022-08-16 | International Business Machines Corporation | Active-active system index management |
CN114591438B (zh) * | 2022-04-25 | 2023-12-05 | 达石药业(广东)有限公司 | 一种采用阳离子交换层析法纯化双特异性抗体的方法 |
CN115850493B (zh) * | 2022-11-08 | 2024-03-12 | 江苏耀海生物制药有限公司 | 一种二价纳米抗体Cablivi的分离纯化方法 |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4515893A (en) | 1979-04-26 | 1985-05-07 | Ortho Pharmaceutical Corporation | Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells |
GB2070818A (en) | 1980-02-04 | 1981-09-09 | Philips Electronic Associated | Regulated power supply for an image intensifier |
WO1984002129A1 (en) | 1982-11-22 | 1984-06-07 | Takeda Chemical Industries Ltd | Human immune interferon protein and process for its preparation |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US4753894A (en) | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
WO1986002068A1 (en) | 1984-09-26 | 1986-04-10 | Takeda Chemical Industries, Ltd. | Mutual separation of proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US5196323A (en) | 1985-04-27 | 1993-03-23 | Boehringer Ingelheim International Gmbh | Process for preparing and purifying alpha-interferon |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US5525338A (en) * | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
CA1283072C (en) | 1986-12-01 | 1991-04-16 | Timothy Durance | Process for the isolation and separation of lysozyme and avidin from eggwhite |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5451662A (en) | 1987-10-23 | 1995-09-19 | Schering Corporation | Method of purifying protein |
US5118796A (en) | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
IT1219874B (it) | 1988-03-18 | 1990-05-24 | Fidia Farmaceutici | Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche |
US5115101A (en) | 1988-06-08 | 1992-05-19 | Miles Inc. | Removal of protein A from antibody preparations |
DE68919361T2 (de) | 1988-06-21 | 1995-05-24 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5112951A (en) | 1989-07-28 | 1992-05-12 | Hybritech Incorporated | Separation of anti-metal chelate antibodies |
US5110913A (en) | 1990-05-25 | 1992-05-05 | Miles Inc. | Antibody purification method |
EP0467466A1 (en) * | 1990-07-16 | 1992-01-22 | Eastman Kodak Company | Method for the purification of immunoreactive labeled thyroxine conjugates |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
JP3457962B2 (ja) | 1991-08-14 | 2003-10-20 | ジェネンテク,インコーポレイテッド | 特定Fcεレセプターのための免疫グロブリン変異体 |
EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
JPH05202098A (ja) | 1992-01-29 | 1993-08-10 | Snow Brand Milk Prod Co Ltd | 乳質原料から生理活性物質の製造法 |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US5279823A (en) * | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
ATE161192T1 (de) | 1992-08-21 | 1998-01-15 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
ATE157455T1 (de) | 1993-12-10 | 1997-09-15 | Genentech Inc | Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika |
ATE164079T1 (de) | 1994-01-18 | 1998-04-15 | Genentech Inc | Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
WO1995023865A1 (en) | 1994-03-03 | 1995-09-08 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
ATE222774T1 (de) | 1996-01-23 | 2002-09-15 | Genentech Inc | Antikörper gegen cd 18 zur verwendung gegen gehirnschlag |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
CN1268639C (zh) | 1996-11-15 | 2006-08-09 | 基因技术股份有限公司 | 神经营养蛋白的纯化 |
EP1516629B1 (en) | 1996-11-27 | 2013-04-03 | Genentech, Inc. | Humanized anti CD-11a antibodies |
DE69739673D1 (de) | 1996-11-27 | 2009-12-31 | Genentech Inc | Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix |
AU740738B2 (en) | 1997-04-07 | 2001-11-15 | Genentech Inc. | Humanized antibodies and methods for forming humanized antibodies |
TR199903123T2 (xx) | 1997-04-07 | 2000-05-22 | Genentech, Inc. | Anti-Vegf antikorlar�. |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
DK0981618T4 (da) | 1997-05-15 | 2011-11-21 | Genentech Inc | Anti-Apo-2-antistof |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
CN103641885A (zh) * | 1998-05-06 | 2014-03-19 | 基因技术股份有限公司 | 用离子交换层析纯化蛋白质 |
CA2333747C (en) | 1998-06-01 | 2008-02-19 | Genentech, Inc. | Separation of protein monomers by use of ion-exchange chromatography |
ES2229784T3 (es) | 1998-06-09 | 2005-04-16 | Statens Serum Institut | Proceso de produccion de inmunoglobulinas para administracion intravenosa y otros productos de inmunoglobulina. |
CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
JP4028237B2 (ja) | 1999-10-29 | 2007-12-26 | ジェネンテック・インコーポレーテッド | 抗前立腺幹細胞抗原(psca)抗体組成物及び使用方法 |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
US6417355B1 (en) * | 2001-04-11 | 2002-07-09 | The United States Of America As Represented By The Secretary Of The Navy | Geminal-dinitro-1-5 diazocine derivatives |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US6770027B2 (en) * | 2001-10-05 | 2004-08-03 | Scimed Life Systems, Inc. | Robotic endoscope with wireless interface |
WO2003033658A2 (en) | 2001-10-17 | 2003-04-24 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
AU2003208415B2 (en) | 2002-02-14 | 2009-05-28 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
JP2005530845A (ja) * | 2002-06-21 | 2005-10-13 | アイデック ファーマシューティカルズ コーポレイション | 抗体を濃縮するための緩衝化処方物およびその使用方法 |
CA2496060C (en) | 2002-09-11 | 2015-08-04 | Genentech, Inc. | Protein purification by ion exchange chromatography |
NZ568769A (en) | 2002-10-17 | 2010-04-30 | Genmab As | Human monoclonal antibodies against CD20 |
MXPA05006306A (es) | 2002-12-13 | 2005-09-21 | Mitra Medical Technology Ab | Agentes de direccionamiento antilinfoma con funciones efectoras y de afinidad enlazados a traves de un reactivo trifuncional. |
AR042485A1 (es) | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
NZ571243A (en) | 2002-12-31 | 2010-04-30 | Altus Pharmaceuticals Inc | Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine |
JPWO2004087761A1 (ja) * | 2003-03-31 | 2006-07-27 | 麒麟麦酒株式会社 | ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製 |
CA2897608C (en) | 2003-05-09 | 2018-07-31 | Duke University | Cd20-specific antibodies and methods employing same |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
EP1651663B1 (en) | 2003-08-08 | 2017-05-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
KR100524074B1 (ko) | 2003-10-01 | 2005-10-26 | 삼성전자주식회사 | 베젤 구조를 가지는 전자기기 |
TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
JP2007532680A (ja) * | 2004-04-16 | 2007-11-15 | ジェネンテック・インコーポレーテッド | 疾患の治療方法 |
CN101022829A (zh) * | 2004-04-16 | 2007-08-22 | 健泰科生物技术公司 | 用抗cd20抗体治疗多软骨炎和多发性单神经炎 |
AU2005318999B2 (en) * | 2004-12-22 | 2012-07-19 | Genentech, Inc. | Methods for producing soluble multi-membrane-spanning proteins |
PL1869065T3 (pl) * | 2005-03-11 | 2020-09-21 | Wyeth Llc | Sposób prowadzenia chromatografii podziałowej ze słabym wiązaniem |
JP5150488B2 (ja) * | 2005-06-17 | 2013-02-20 | ワイス・エルエルシー | Fc領域含有タンパク質を精製する方法 |
US8246983B2 (en) * | 2005-09-02 | 2012-08-21 | Northwestern University | Encapsulated arsenic drugs |
CN101437839A (zh) * | 2006-03-20 | 2009-05-20 | 米德列斯公司 | 蛋白质纯化 |
EP3088410A3 (en) † | 2006-04-05 | 2016-12-28 | AbbVie Biotechnology Ltd | Antibody purification |
UA99262C2 (uk) * | 2006-08-28 | 2012-08-10 | Арес Трейдінг С.А. | СПОСІБ ЗМЕНШЕННЯ КОНЦЕНТРАЦІЇ ВІЛЬНИХ Fc-ЧАСТИН В РІДИНІ, ЩО МІСТИТЬ Fc-ВМІСНИЙ БІЛОК |
US8620738B2 (en) | 2006-08-31 | 2013-12-31 | Visa U.S.A. Inc | Loyalty program incentive determination |
CA2682170A1 (en) * | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
EP3441402A1 (en) | 2007-10-30 | 2019-02-13 | Genentech, Inc. | Antibody purification by cation exchange chromatography |
WO2015198451A1 (ja) | 2014-06-26 | 2015-12-30 | 楽天株式会社 | 情報処理装置、情報処理方法及び情報処理プログラム |
-
2008
- 2008-10-29 EP EP18151178.3A patent/EP3441402A1/en not_active Withdrawn
- 2008-10-29 TW TW097141614A patent/TWI448330B/zh active
- 2008-10-29 PL PL12189190T patent/PL2565206T3/pl unknown
- 2008-10-29 HU HUE12189190A patent/HUE027668T2/en unknown
- 2008-10-29 SG SG2011073087A patent/SG175597A1/en unknown
- 2008-10-29 DK DK12189190.7T patent/DK2565206T3/da active
- 2008-10-29 CN CN201510941252.9A patent/CN105315323A/zh active Pending
- 2008-10-29 AR ARP080104725A patent/AR069097A1/es active IP Right Grant
- 2008-10-29 KR KR1020147036127A patent/KR20150008503A/ko not_active Application Discontinuation
- 2008-10-29 ES ES14189095.4T patent/ES2666170T3/es active Active
- 2008-10-29 HU HUE08844379A patent/HUE024877T2/en unknown
- 2008-10-29 SG SG10201401690XA patent/SG10201401690XA/en unknown
- 2008-10-29 PL PL08844379T patent/PL2215117T5/pl unknown
- 2008-10-29 EP EP12189190.7A patent/EP2565206B1/en active Active
- 2008-10-29 CN CN201310495290.7A patent/CN103554215B/zh active Active
- 2008-10-29 SI SI200831381T patent/SI2215117T2/en unknown
- 2008-10-29 PE PE2008001848A patent/PE20091434A1/es active IP Right Grant
- 2008-10-29 KR KR1020107011765A patent/KR101241486B1/ko active IP Right Grant
- 2008-10-29 MX MX2010004740A patent/MX2010004740A/es active IP Right Grant
- 2008-10-29 ES ES12189190.7T patent/ES2572958T3/es active Active
- 2008-10-29 CL CL2008003218A patent/CL2008003218A1/es unknown
- 2008-10-29 ME MEP-2015-34A patent/ME02101B/me unknown
- 2008-10-29 KR KR1020127028627A patent/KR20140015166A/ko not_active Application Discontinuation
- 2008-10-29 ES ES08844379.1T patent/ES2533266T5/es active Active
- 2008-10-29 AU AU2008318865A patent/AU2008318865B2/en active Active
- 2008-10-29 CA CA2703279A patent/CA2703279C/en active Active
- 2008-10-29 HU HUE14189095A patent/HUE037409T2/hu unknown
- 2008-10-29 WO PCT/US2008/081516 patent/WO2009058812A1/en active Application Filing
- 2008-10-29 RU RU2010121816/10A patent/RU2498991C2/ru active
- 2008-10-29 JP JP2010532193A patent/JP5237382B2/ja active Active
- 2008-10-29 RS RS20150156A patent/RS53850B2/sr unknown
- 2008-10-29 SI SI200831945T patent/SI2840090T1/en unknown
- 2008-10-29 DK DK08844379.1T patent/DK2215117T4/da active
- 2008-10-29 EP EP14189095.4A patent/EP2840090B1/en active Active
- 2008-10-29 CN CN200880119331XA patent/CN101889025B/zh active Active
- 2008-10-29 EP EP08844379.1A patent/EP2215117B2/en active Active
- 2008-10-29 NZ NZ584839A patent/NZ584839A/en unknown
- 2008-10-29 BR BRPI0817182 patent/BRPI0817182A2/pt not_active Application Discontinuation
- 2008-10-29 PL PL14189095T patent/PL2840090T3/pl unknown
- 2008-10-29 TW TW103117553A patent/TWI554517B/zh active
- 2008-10-29 US US12/260,623 patent/US20090148435A1/en not_active Abandoned
- 2008-10-29 PT PT88443791T patent/PT2215117E/pt unknown
- 2008-10-29 SI SI200831634A patent/SI2565206T1/sl unknown
- 2008-10-29 DK DK14189095.4T patent/DK2840090T3/da active
-
2010
- 2010-04-22 ZA ZA2010/02850A patent/ZA201002850B/en unknown
- 2010-04-25 IL IL205310A patent/IL205310A0/en unknown
- 2010-05-21 CO CO10061141A patent/CO6280422A2/es active IP Right Grant
- 2010-10-28 HK HK10110121.9A patent/HK1143821A1/xx active IP Right Maintenance
- 2010-10-28 HK HK13109765.9A patent/HK1182401A1/zh unknown
-
2011
- 2011-03-23 ZA ZA2011/02169A patent/ZA201102169B/en unknown
-
2013
- 2013-03-21 JP JP2013059102A patent/JP2013173747A/ja not_active Withdrawn
- 2013-06-03 PH PH12013501128A patent/PH12013501128A1/en unknown
-
2014
- 2014-09-30 IL IL234902A patent/IL234902A0/en unknown
- 2014-09-30 IL IL234901A patent/IL234901A0/en unknown
- 2014-11-03 US US14/531,880 patent/US9896478B2/en active Active
-
2015
- 2015-02-19 JP JP2015030880A patent/JP5885864B2/ja active Active
- 2015-02-19 JP JP2015030881A patent/JP2015155406A/ja not_active Withdrawn
- 2015-03-12 HR HRP20150282TT patent/HRP20150282T4/hr unknown
- 2015-03-19 CY CY20151100275T patent/CY1116129T1/el unknown
- 2015-06-18 IL IL239495A patent/IL239495B/en not_active IP Right Cessation
- 2015-07-28 HK HK15107237.1A patent/HK1206753A1/xx unknown
-
2016
- 2016-07-12 JP JP2016137986A patent/JP2017019790A/ja active Pending
- 2016-08-08 HK HK16109407.0A patent/HK1221234A1/zh unknown
-
2017
- 2017-12-21 US US15/850,885 patent/US20180118781A1/en not_active Abandoned
-
2018
- 2018-03-09 AR ARP180100555A patent/AR111171A2/es unknown
- 2018-06-18 HR HRP20180943TT patent/HRP20180943T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2840090T3 (da) | Antistofrensning ved kationbytningskromatografi | |
EP2321337B9 (en) | Methods for removing a contaminant using protein displacement ion exchange membrane chromatography | |
AU2012227163B2 (en) | Antibody purification by cation exchange chromatography | |
AU2015218432A1 (en) | Antibody purification by cation exchange chromatography |